Xevinapant plus nivolumab in patients with advanced solid tumors who progressed on prior anti-PD-1/PD-L1 treatment: Results of a dose-optimization, exploratory phase 1b/2 trial

Emiliano Calvo Aller,1 Glenn Hanna*,2 Maria Viento Villar,4 Caroline Ewen,3 Victor Moreno,2 Chul Kim,7 Shuchi Gulati,6 Daniel Morgenstern,9 Ana Acuna-Villaorduna,1 Filippe Casier,1 Denice Jones,12 Florilene Bouisset,12 Daniela Sahlender,1 Elisabeth Rouits,1 Dany Spaggiari,1 Lars Damstrup,12 Carlos-Alberto Gomez-Roca.1

Background Anticancer agents that render cancer cells susceptible to apoptosis and increase tumor immunity may enhance clinical responses to immune checkpoint inhibitors. In this phase 1b/2 trial, we investigated the antitumor activity and safety of xevinapant, a first-in-class, potent, oral, small-molecule inhibitor of apoptosis proteins inhibitor which restores cancer cell sensitivity to apoptosis, in combination with the anti-PD-1 antibody nivolumab.

Methods Eligible patients had histologically confirmed advanced or metastatic solid tumors that progressed on prior anti-PD-1/PD-L1 treatment, including small cell lung cancer (cohort 1), squamous cell carcinoma of the head and neck (cohort 2), gastrointestinal cancers with known microsatellite-high (MSI-H)/mismatch repair deficiency (MMRd) or other DNA-damage response (DDR) abnormalities (cohort 3), or platinum-resistant epithelial ovarian, endometrial, primary peritoneal or cervical cancer (with known MSI-H/ MMRd, BRCA1/2 mutations, or other DDR abnormalities; cohort 4). In the dose-escalation part of the trial (part A), patients received xevinapant 150 or 200 mg/day on days 1-10 and 15-24 plus nivolumab 240 mg on days 1 and 15 of a 28-day cycle. The primary endpoint of part A was to determine the recommended phase 2 dose (RP2D). In the phase 2 basket trial (part B), patients received xevinapant plus nivolumab at the RP2D; the primary endpoint was objective response rate (ORR).

Results Eleven patients were enrolled in part A; 3 patients received xevinapant 150 mg/day and 8 received 200 mg/day. No dose-limiting toxicities were observed during the observation period (28 days) or grade ≥3 treatment-related adverse events (TRAEs) were reported. The RP2D was established as xevinapant 200 mg/day (days 1-10 and 15-24) plus nivolumab 240 mg (days 1 and 15) per 28-day cycle. In part B, 35 patients (n=8 cohorts 1-3, n=11 cohort 4) received xevinapant plus nivolumab at the RP2D. Most patients (60.0%) had stage IV disease and all patients had received prior chemotherapy treatment. At data cutoff (April 6, 2022), the ORR was 2.9%, with 1 partial response (cohort 4); 15 patients (42.9%) had stable disease. Thirty-four patients (97.1%) had discontinued treatment; the most common reason was disease progression (26 patients; 74.3%). Median PFS across cohorts was 1.9 months (95% CI, 1.7-2.7); median OS was 11.7 months (95% CI, 6.0-15.9). TRAEs occurred in 30 patients (85.7%); grade ≥3 TRAEs in 9 patients (25.7%). No treatment-related deaths were reported.

Conclusions Xevinapant plus nivolumab had a tolerable safety profile in patients with heavily pretreated solid tumors but limited clinical activity in this immunotherapy-refractory population.

Acknowledgements This trial was sponsored by Debiopharm. Medical writing support was provided by Sophie Saunders of ClinicalThinking and was funded by the healthcare business of Merck KGaA, Darmstadt, Germany (CrossRef Funder ID: 10.13039/100009945).

Trial Registration NCT04122625 (ClinicalTrials.gov)

REFERENCES

Ethics Approval The trial protocol was approved by the independent ethics committee or institutional review board at each participating center.